(52 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | {{Team:ASIJ_Tokyo/ | + | {{ASIJ_Tokyo/CSS}} |
+ | {{:Team:ASIJ_Tokyo/bar}} | ||
+ | |||
<html> | <html> | ||
− | |||
− | <style> | + | <style type="text/css"> |
/*page preset==============================================*/ | /*page preset==============================================*/ | ||
#content { | #content { | ||
− | + | width: 100%; | |
− | + | margin: auto; | |
− | + | background: none; | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
border: none; | border: none; | ||
− | + | padding: 0; | |
} | } | ||
Line 27: | Line 20: | ||
background-repeat: repeat, repeat; | background-repeat: repeat, repeat; | ||
background-size: 100%; | background-size: 100%; | ||
− | + | ||
padding: 0; | padding: 0; | ||
margin: 0; | margin: 0; | ||
Line 36: | Line 29: | ||
margin-right: 10%; | margin-right: 10%; | ||
} | } | ||
+ | |||
footer { | footer { | ||
border-top: 2px dotted #fff; | border-top: 2px dotted #fff; | ||
Line 57: | Line 51: | ||
color: #88C1EF; | color: #88C1EF; | ||
} | } | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
Line 164: | Line 56: | ||
− | #title | + | #title h1 { |
− | font-size: 90px; | + | font-size: 90px !important; |
color: #071f4e; | color: #071f4e; | ||
text-align: right; | text-align: right; | ||
Line 172: | Line 64: | ||
letter-spacing: 5px; | letter-spacing: 5px; | ||
line-height: normal; | line-height: normal; | ||
− | padding-top: | + | padding-top: 70px; |
padding-bottom: 0; | padding-bottom: 0; | ||
+ | margin-bottom: -5px; | ||
} | } | ||
Line 179: | Line 72: | ||
margin-right: 0; | margin-right: 0; | ||
margin-left: 0; | margin-left: 0; | ||
− | margin-top: | + | margin-top: 4%; |
margin-bottom: 5%; | margin-bottom: 5%; | ||
background: none; | background: none; | ||
font-size: 100%; | font-size: 100%; | ||
+ | border: none; | ||
} | } | ||
Line 192: | Line 86: | ||
} | } | ||
− | #subtitle | + | #subtitle h2 { |
− | + | text-align: right; | |
− | + | color: #071f4e; | |
− | + | font-size: 15px; | |
+ | line-height: 30px; | ||
+ | padding-top: 0; | ||
} | } | ||
Line 204: | Line 100: | ||
} | } | ||
− | #abstract | + | #abstract h3 { |
− | + | text-align: center; | |
− | + | color: white; | |
+ | font-size: 30px; | ||
+ | letter-spacing: 2px; | ||
+ | font-weight: 100; | ||
+ | margin-bottom: 15px; | ||
} | } | ||
− | # | + | #HQ_page p { |
− | + | ||
− | + | font-size: 18px; | |
− | + | text-align: justify; | |
− | + | ||
− | + | ||
− | + | ||
} | } | ||
+ | h6 { | ||
+ | font-size: 10px; | ||
+ | font-weight: 100; | ||
+ | float: right; | ||
+ | color: #4B7FAD; | ||
+ | } | ||
+ | |||
+ | #igem { | ||
+ | height: 300px; | ||
+ | z-index: -2; | ||
+ | position: absolute; | ||
+ | top: 9%; | ||
+ | right: 27%; | ||
+ | } | ||
</style> | </style> | ||
<body background="https://static.igem.org/mediawiki/2018/b/b0/T--ASIJ_Tokyo--OfficialBackground.jpeg"> | <body background="https://static.igem.org/mediawiki/2018/b/b0/T--ASIJ_Tokyo--OfficialBackground.jpeg"> | ||
− | |||
<div class="wrapper"> | <div class="wrapper"> | ||
− | + | <img id="igem" src="https://static.igem.org/mediawiki/2018/8/81/T--ASIJ_Tokyo--%2Aigem_asij_logo%2A.png"> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<table> | <table> | ||
<tr> | <tr> | ||
<td rowspan="2"> | <td rowspan="2"> | ||
− | <img id="liver" src="https://static.igem.org/mediawiki/2018/ | + | <img id="liver" src="https://static.igem.org/mediawiki/2018/7/7a/T--ASIJ_Tokyo--%2ALIVER%2A%28resized%29.png" height="375px" alt="liver"> |
− | <td id="title">< | + | <td id="title"><h1>A1-AT<br>de<span style="color:rgb(182, 9, 23)">LIVER</span>y </h1></td> |
</td> | </td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
− | <td id="subtitle">< | + | <td id="subtitle"><h2> Using CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency </h2></td> |
</tr> | </tr> | ||
</table> | </table> | ||
<div id="abstract"> | <div id="abstract"> | ||
<h3> ABSTRACT </h3> | <h3> ABSTRACT </h3> | ||
− | <p> Alpha-1 | + | <p> Alpha-1 antitrypsin (A1AT) deficiency is a genetic disorder that arises from a single base pair mutation in the SERPINA gene. The disease results in the production of a form of A1AT prone to polymerization, which builds up in liver cells and is unable to inhibit proteases in the lungs. The lack of antitrypsin leads to damage in both the liver and the lungs. Using CRISPR-Cas9 technology, we attempted to fix the point mutation in SERPINA1 so that proper antitrypsin can be produced. We will test our system in E. Coli cells using histidine tags, osmY secretion tags, and GFP as a reporter. We hope to design a liver organ bud using iPS cell technology to deliver functional antitrypsin through collaboration with Dr. Kagimoto of Healios Japan KK. |
</div> | </div> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
+ | <footer> | ||
+ | <img id=footer_logo src="https://static.igem.org/mediawiki/2018/4/4b/T--ASIJ_Tokyo--TeamLogo.png" alt="iGEMlogo"> | ||
+ | <h6>Icon used in the background made by <a href="https://www.flaticon.com/authors/ddara">dDara</a>from <a href="www.flaticon.com">www.flaticon.com</a></h6> | ||
+ | </footer> | ||
+ | |||
+ | </div> | ||
</body> | </body> | ||
</html> | </html> |
Latest revision as of 04:16, 17 October 2018
A1-AT |
|
Using CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency |
ABSTRACT
Alpha-1 antitrypsin (A1AT) deficiency is a genetic disorder that arises from a single base pair mutation in the SERPINA gene. The disease results in the production of a form of A1AT prone to polymerization, which builds up in liver cells and is unable to inhibit proteases in the lungs. The lack of antitrypsin leads to damage in both the liver and the lungs. Using CRISPR-Cas9 technology, we attempted to fix the point mutation in SERPINA1 so that proper antitrypsin can be produced. We will test our system in E. Coli cells using histidine tags, osmY secretion tags, and GFP as a reporter. We hope to design a liver organ bud using iPS cell technology to deliver functional antitrypsin through collaboration with Dr. Kagimoto of Healios Japan KK.